Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
URGN 
UroGen Pharma Ltd (URGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: URGN (3-star) is a SELL. SELL since 1 days. Simulated Profits (15.77%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $35.25
1 Year Target Price $35.25
| 5 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.07% | Avg. Invested days 26 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.08B USD | Price to earnings Ratio - | 1Y Target Price 35.25 |
Price to earnings Ratio - | 1Y Target Price 35.25 | ||
Volume (30-day avg) 8 | Beta 1.23 | 52 Weeks Range 3.42 - 30.00 | Updated Date 12/6/2025 |
52 Weeks Range 3.42 - 30.00 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.47 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-17 | When - | Estimate -0.6434 | Actual -0.69 |
Profitability
Profit Margin -170.59% | Operating Margin (TTM) -99.65% |
Management Effectiveness
Return on Assets (TTM) -33.96% | Return on Equity (TTM) -1481.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1141115520 | Price to Sales(TTM) 11.14 |
Enterprise Value 1141115520 | Price to Sales(TTM) 11.14 | ||
Enterprise Value to Revenue 11.82 | Enterprise Value to EBITDA -2.63 | Shares Outstanding 46808892 | Shares Floating 37059068 |
Shares Outstanding 46808892 | Shares Floating 37059068 | ||
Percent Insiders 6.78 | Percent Institutions 101.13 |
Upturn AI SWOT
UroGen Pharma Ltd
Company Overview
History and Background
UroGen Pharma Ltd. is a biopharmaceutical company founded in 2004. It focuses on developing and commercializing novel solutions to treat urothelial cancers and other urological diseases. A significant milestone was the FDA approval of Jelmyto (mitomycin gel) in 2020, the first non-surgical treatment for low-grade upper tract urothelial cancer (LG UTUC). The company continues to expand its research and development efforts in the field of urology.
Core Business Areas
- Uro-Oncology: Focuses on developing and commercializing treatments for urothelial cancers, primarily through its proprietary RTGel technology.
- Specialty Urology: Encompasses the development of therapies for other urological conditions beyond cancer.
Leadership and Structure
Liz Barrett is the CEO of UroGen Pharma. The company has a standard organizational structure with departments focused on research and development, clinical operations, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Jelmyto (mitomycin gel): Jelmyto is a reverse-thermal gel formulation of mitomycin approved for the treatment of low-grade upper tract urothelial cancer (LG UTUC). It provides a non-surgical option for patients. Revenue for 2023 was $87.4 million. Key competitors include conventional surgical treatments and other off-label intravesical chemotherapies. There is no readily available market share data.
Market Dynamics
Industry Overview
The uro-oncology market is growing due to the increasing incidence of bladder and upper tract urothelial cancers. There's a significant unmet need for non-surgical treatment options, driving innovation and market expansion.
Positioning
UroGen Pharma is positioned as a leader in non-surgical treatments for urothelial cancers, particularly with its Jelmyto product. Its RTGel technology provides a competitive advantage.
Total Addressable Market (TAM)
The TAM for UTUC treatment is estimated to be in the hundreds of millions of dollars annually, and the overall bladder cancer market is significantly larger. UroGen is positioned to capture a growing share of this market with Jelmyto.
Upturn SWOT Analysis
Strengths
- FDA-approved product (Jelmyto)
- Proprietary RTGel technology
- First-mover advantage in non-surgical LG UTUC treatment
- Strong clinical data supporting Jelmyto's efficacy
Weaknesses
- Reliance on a single product (Jelmyto)
- Relatively small commercial organization
- Potential competition from emerging therapies
- Dependence on reimbursement approvals for market access
Opportunities
- Expansion of Jelmyto's indications
- Development of new products using RTGel technology
- Partnerships and collaborations with larger pharmaceutical companies
- Geographic expansion into new markets
Threats
- Competition from generic mitomycin formulations
- Unfavorable changes in reimbursement policies
- Clinical trial failures for pipeline products
- Regulatory hurdles for new product approvals
Competitors and Market Share
Key Competitors
- BCRX
- ADXS
- CLVS
Competitive Landscape
UroGen's advantage lies in its novel RTGel technology and first-mover advantage with Jelmyto. Disadvantages include reliance on a single product and competition from larger, more established pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: UroGen's growth has been driven by the commercialization of Jelmyto. Revenue has increased steadily since its launch.
Future Projections: Analysts project continued revenue growth for Jelmyto as it gains wider acceptance and market penetration. Future growth is also dependent on the success of the company's pipeline programs.
Recent Initiatives: UroGen is focused on expanding the use of Jelmyto and advancing its pipeline programs, including UGN-102 (mitomycin reverse thermal gel) for LG-UTUC.
Summary
UroGen Pharma is a biopharmaceutical company with a focus on uro-oncology, particularly the treatment of low-grade upper tract urothelial cancer (LG UTUC). Jelmyto is driving revenue, but the company is not yet profitable. The company holds a promising pipeline program. Further growth depends on successful execution of pipeline and positive developments in reimbursement policies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- UroGen Pharma Ltd. Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About UroGen Pharma Ltd
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2017-05-04 | President, CEO & Director Ms. Elizabeth A. Barrett | ||
Sector Healthcare | Industry Biotechnology | Full time employees 287 | Website https://www.urogen.com |
Full time employees 287 | Website https://www.urogen.com | ||
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.